These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30987979)

  • 1. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
    Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
    Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
    Namkoong J; Shin SS; Lee HJ; Marín YE; Wall BA; Goydos JS; Chen S
    Cancer Res; 2007 Mar; 67(5):2298-305. PubMed ID: 17332361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
    Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.
    Le MN; Chan JL; Rosenberg SA; Nabatian AS; Merrigan KT; Cohen-Solal KA; Goydos JS
    J Invest Dermatol; 2010 Sep; 130(9):2240-9. PubMed ID: 20505744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.
    Wall BA; Wangari-Talbot J; Shin SS; Schiff D; Sierra J; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
    Pigment Cell Melanoma Res; 2014 Mar; 27(2):263-74. PubMed ID: 24330389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.
    Martino JJ; Wall BA; Mastrantoni E; Wilimczyk BJ; La Cava SN; Degenhardt K; White E; Chen S
    Oncogene; 2013 Sep; 32(37):4366-76. PubMed ID: 23085756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
    Wen Y; Li J; Koo J; Shin SS; Lin Y; Jeong BS; Mehnert JM; Chen S; Cohen-Sola KA; Goydos JS
    Cancer Res; 2014 May; 74(9):2499-509. PubMed ID: 24491800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional effects of GRM1 suppression in human melanoma cells.
    Wangari-Talbot J; Wall BA; Goydos JS; Chen S
    Mol Cancer Res; 2012 Nov; 10(11):1440-50. PubMed ID: 22798429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.
    Teh JL; Shah R; La Cava S; Dolfi SC; Mehta MS; Kongara S; Price S; Ganesan S; Reuhl KR; Hirshfield KM; Karantza V; Chen S
    Breast Cancer Res Treat; 2015 May; 151(1):57-73. PubMed ID: 25859923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Signaling Cascades Prompted by Glutaminolysis in Cancer.
    Shah R; Chen S
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32937954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
    Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
    Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.
    Khan AJ; Wall B; Ahlawat S; Green C; Schiff D; Mehnert JM; Goydos JS; Chen S; Haffty BG
    Clin Cancer Res; 2011 Apr; 17(7):1807-14. PubMed ID: 21325066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma.
    Abushahba W; Olabisi OO; Jeong BS; Boregowda RK; Wen Y; Liu F; Goydos JS; Lasfar A; Cohen-Solal KA
    PLoS One; 2012; 7(10):e47312. PubMed ID: 23077590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.
    Shin SS; Namkoong J; Wall BA; Gleason R; Lee HJ; Chen S
    Pigment Cell Melanoma Res; 2008 Jun; 21(3):368-78. PubMed ID: 18435704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.
    Marín YE; Namkoong J; Cohen-Solal K; Shin SS; Martino JJ; Oka M; Chen S
    Cell Signal; 2006 Aug; 18(8):1279-86. PubMed ID: 16305822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.
    Mehnert JM; Silk AW; Lee JH; Dudek L; Jeong BS; Li J; Schenkel JM; Sadimin E; Kane M; Lin H; Shih WJ; Zloza A; Chen S; Goydos JS
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):534-540. PubMed ID: 29453787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.